Investigators unanimously voted to move to the 1800 mg dose after they reviewed the safety profile of Veyonda? in 12 patients from Cohorts 3 and 4.
The Company will be reporting formally on efficacy in due course, with the overall objective being to use Veyonda to block the cy-to-kine release syndrome (so-called ‘cytokine storm’) that leads to patients requiring intensive care, and is a primary cause of the multi-organ damage responsible for much of the long-term disability and death in Covid-19 patients.
Shares in Noxopharm (ASX:NOX) are trading 1.9 per cent higher at 53 cents.